112 related articles for article (PubMed ID: 22995933)
21. Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study.
Baloush-Kleinman V; Levine SZ; Roe D; Shnitt D; Weizman A; Poyurovsky M
Schizophr Res; 2011 Aug; 130(1-3):176-81. PubMed ID: 21636254
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
23. Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates.
Emsley R; Rabinowitz J; Medori R;
Schizophr Res; 2007 Jan; 89(1-3):129-39. PubMed ID: 17095194
[TBL] [Abstract][Full Text] [Related]
24. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial.
Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
Schizophr Res; 2014 Feb; 152(2-3):450-7. PubMed ID: 24412468
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis.
Citrome L; Meng X; Hochfeld M
Schizophr Res; 2011 Sep; 131(1-3):75-81. PubMed ID: 21700430
[TBL] [Abstract][Full Text] [Related]
26. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial.
Liu F; Guo X; Wu R; Ou J; Zheng Y; Zhang B; Xie L; Zhang L; Yang L; Yang S; Yang J; Ruan Y; Zeng Y; Xu X; Zhao J
Schizophr Res; 2014 Mar; 153(1-3):169-76. PubMed ID: 24503176
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
[TBL] [Abstract][Full Text] [Related]
28. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: a randomized controlled pilot study.
Mogg A; Purvis R; Eranti S; Contell F; Taylor JP; Nicholson T; Brown RG; McLoughlin DM
Schizophr Res; 2007 Jul; 93(1-3):221-8. PubMed ID: 17478080
[TBL] [Abstract][Full Text] [Related]
29. Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia.
Ruberg SJ; Chen L; Stauffer V; Ascher-Svanum H; Kollack-Walker S; Conley RR; Kane J; Kinon BJ
BMC Psychiatry; 2011 Feb; 11():23. PubMed ID: 21306626
[TBL] [Abstract][Full Text] [Related]
30. Treatment response trajectories and their antecedents in recent-onset psychosis: a 2-year prospective study.
Levine SZ; Rabinowitz J; Case M; Ascher-Svanum H
J Clin Psychopharmacol; 2010 Aug; 30(4):446-9. PubMed ID: 20631562
[TBL] [Abstract][Full Text] [Related]
31. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
Khodaie-Ardakani MR; Seddighi S; Modabbernia A; Rezaei F; Salehi B; Ashrafi M; Shams-Alizadeh N; Mohammad-Karimi M; Esfandiari GR; Hajiaghaee R; Akhondzadeh S
J Psychiatr Res; 2013 Apr; 47(4):472-8. PubMed ID: 23375406
[TBL] [Abstract][Full Text] [Related]
32. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia.
Lieberman JA; Papadakis K; Csernansky J; Litman R; Volavka J; Jia XD; Gage A;
Neuropsychopharmacology; 2009 Apr; 34(5):1322-9. PubMed ID: 19005465
[TBL] [Abstract][Full Text] [Related]
33. Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: analysis of amisulpride vs placebo in three clinical trials.
Levine SZ; Leucht S
Schizophr Res; 2014 Jun; 156(1):107-14. PubMed ID: 24794879
[TBL] [Abstract][Full Text] [Related]
34. A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial.
Stahl SM; Malla A; Newcomer JW; Potkin SG; Weiden PJ; Harvey PD; Loebel A; Watsky E; Siu CO; Romano S
J Clin Psychopharmacol; 2010 Aug; 30(4):425-30. PubMed ID: 20571437
[TBL] [Abstract][Full Text] [Related]
35. Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol.
Riedel M; Mayr A; Seemüller F; Maier W; Klingberg S; Heuser I; Klosterkötter J; Gastpar M; Schmitt A; Sauer H; Schneider F; Gaebel W; Jäger M; Möller HJ; Schennach-Wolff R
World J Biol Psychiatry; 2012 Jan; 13(1):30-8. PubMed ID: 21568628
[TBL] [Abstract][Full Text] [Related]
36. Placebo effects in adult and adolescent patients with schizophrenia: combined analysis of nine RCTs.
Kubo K; Fleischhacker WW; Suzuki T; Yasui-Furukori N; Mimura M; Uchida H
Acta Psychiatr Scand; 2019 Feb; 139(2):108-116. PubMed ID: 30198163
[TBL] [Abstract][Full Text] [Related]
37. Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study.
Emsley R; Oosthuizen PP; Koen L; Niehaus DJ; Martinez G
J Clin Psychiatry; 2012 Apr; 73(4):e541-7. PubMed ID: 22579160
[TBL] [Abstract][Full Text] [Related]
38. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
[TBL] [Abstract][Full Text] [Related]
39. Early prediction of clinical response in first episode schizophrenia (FES) patients receiving olanzapine.
Subeesh V; Maheswari E; Singh H; Saraswathy GR; Reddy N; Chiranjeevi P
Int J Psychiatry Clin Pract; 2020 Sep; 24(3):309-314. PubMed ID: 32338556
[No Abstract] [Full Text] [Related]
40. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
Constantine RJ; Andel R; McPherson M; Tandon R
Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]